Ruiz García, YaraSohn, Woo-YunSeib, Kate LTaha, Muhamed-KheirVazquez-Moreno, Julio AlbertoSilva de Lemos, Ana PaulaVadivelu, KumaranPizza, MariagraziaRappuoli, RinoBekkat-Berkani, Rafik2022-05-062022-05-062021-10-29NPJ Vaccines 2021 Oct 29;6(1):130.http://hdl.handle.net/20.500.12105/14292Infections with Neisseria meningitidis and Neisseria gonorrhoeae have different clinical manifestations, but the bacteria share up to 80-90% genome sequence identity. The recombinant meningococcal serogroup B (MenB) vaccine 4CMenB consists of four antigenic components that can be present in non-B meningococcal and gonococcal strains. This comprehensive review summarizes scientific evidence on the genotypic and phenotypic similarities between vaccine antigens and their homologs expressed by non-B meningococcal and gonococcal strains. It also includes immune responses of 4CMenB-vaccinated individuals and effectiveness and impact of 4CMenB against these strains. Varying degrees of strain coverage were estimated depending on the non-B meningococcal serogroup and antigenic repertoire. 4CMenB elicits immune responses against non-B meningococcal serogroups and N. gonorrhoeae. Real-world evidence showed risk reductions of 69% for meningococcal serogroup W clonal complex 11 disease and 40% for gonorrhea after 4CMenB immunization. In conclusion, functional antibody activity and real-world evidence indicate that 4CMenB has the potential to provide some protection beyond MenB disease.engVoRhttp://creativecommons.org/licenses/by/4.0/Atribución 4.0 Internacional347163366113010.1038/s41541-021-00388-32059-0105NPJ Vaccinesopen access